FULC

Fulcrum Therapeutics, Inc.

10.98 USD
-0.01 (-0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Fulcrum Therapeutics, Inc. stock is up 36.91% since 30 days ago. The next earnings date is May 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 March’s closed higher than February.

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin.